David R. Jones

发表

Challenges and approaches for the development of safer immunomodulatory biologics

M. Pirmohamed, S. Holgate, R. Weaver, 2013, Nature Reviews Drug Discovery.

Application of Microphysiological Systems to Enhance Safety Assessment in Drug Discovery.

Uwe Marx, Eva-Maria Dehne, Susan Gibbs, 2018, Annual review of pharmacology and toxicology.

Nonclinical Toxicological Support for Phase I Trials

David R. Jones, J. Mcblane, J. McBlane, 2014 .

Preclinical imaging methods for assessing the safety and efficacy of regenerative medicine therapies

Neal C Burton, Julie Holder, Neal C. Burton, 2017, npj Regenerative Medicine.

Concise Review: Workshop Review: Understanding and Assessing the Risks of Stem Cell‐Based Therapies

Dominic P. Williams, P. Andrews, D. Hay, 2015, Stem cells translational medicine.

REVIEW Assessing the Potential to Induce Respiratory Hypersensitivity

I. Kimber, David R. Jones, M. Selgrade, 2006 .

Neurofunctional test batteries in safety pharmacology - Current and emerging considerations for the drug development process.

S. Authier, S. Jackson, J. Valentin, 2019, Journal of pharmacological and toxicological methods.

Opportunities for use of one species for longer-term toxicology testing during drug development: A cross-industry evaluation.

R. Weaver, W. Casey, O. Doehr, 2020, Regulatory toxicology and pharmacology : RTP.

The 3T3 neutral red uptake phototoxicity test: practical experience and implications for phototoxicity testing--the report of an ECVAM-EFPIA workshop.

V. Rogiers, W. Muster, D. Bauer, 2012, Regulatory toxicology and pharmacology : RTP.

Managing the challenge of chemically reactive metabolites in drug development

Ian D. Wilson, Alan Boobis, Chris E. P. Goldring, 2011, Nature Reviews Drug Discovery.

A framework for the development of effective anti-metastatic agents

Jacqueline A. Hall, Andrew D. Westwell, Jacqui A. Shaw, 2018, Nature Reviews Clinical Oncology.

Is there a role for the no observed adverse effect level in safety pharmacology?

S. Authier, T. Baird, J. Valentin, 2020, Journal of pharmacological and toxicological methods.

Genetic toxicology in silico protocol.

Raymond R Tice, Naomi L Kruhlak, Lidiya Stavitskaya, 2019, Regulatory toxicology and pharmacology : RTP.

Assessing drug safety in human tissues — what are the barriers?

A. Holmes, David R. Jones, David Jones, 2015, Nature Reviews Drug Discovery.

Assessing the potential to induce respiratory hypersensitivity.

I. Kimber, David R. Jones, M. Selgrade, 2006, Toxicological sciences : an official journal of the Society of Toxicology.

Critical analysis of carcinogenicity study outcomes. Relationship with pharmacological properties

Peter Kasper, Jan Willem van der Laan, P. Kasper, 2016, Critical reviews in toxicology.

Current Trends of Practices in Nonclinical Toxicology: An Industry Survey

S. Authier, W. J. Brock, W. Halpern, 2021, International journal of toxicology.

Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trials.

Fiona Sewell, Sally Robinson, Beatriz Silva Lima, 2014, Regulatory toxicology and pharmacology : RTP.

In silico toxicology protocols.

Tudor I. Oprea, Naomi L Kruhlak, Lidiya Stavitskaya, 2018, Regulatory toxicology and pharmacology : RTP.

The Nonclinical Evaluation of Biotechnology‐Derived Pharmaceuticals, Moving on after the TeGenero Case*

R. Thorpe, C. Herberts, R. Stebbings, 2014 .

Exploring the Definition of “Similar Toxicities”: Case Studies Illustrating Industry and Regulatory Interpretation of ICH S6(R1) for Long-Term Toxicity Studies in One or Two Species

David R. Jones, F. Sewell, H. Prior, 2022, International journal of toxicology.

Non-clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals: ICH M3 and M3(R2)

David R. Jones, P. Sjöberg, 2013 .

Predicting the Safety of Medicines in Pregnancy: a Workshop Report.

A. Piersma, M. Pirmohamed, P. Barrow, 2020, Reproductive toxicology.

New regulatory framework for cancer drug development.

David R. Jones, Paul S. Jones, 2012, Drug discovery today.

Application of Microphysiological Systems to Enhance Safety Assessment in Drug Discovery.

Jerome T. Mettetal, Kristin M. Fabre, Dominic P. Williams, 2018, Annual review of pharmacology and toxicology.

Critical analysis of carcinogenicity study outcomes. Relationship with pharmacological properties

P. Kasper, J. W. van der Laan, B. Silva Lima, 2016, Critical reviews in toxicology.

Preclinical screening for antidepressant activity - shifting focus away from the Forced Swim Test to the use of translational biomarkers.

M. Tricklebank, David R. Jones, F. Sewell, 2021, Regulatory toxicology and pharmacology : RTP.

Association of Inhalation Toxicologists’ (AIT) review of regulatory aspects for inhalation toxicology studies

David R. Jones, P. Baldrick, 2013, Inhalation toxicology.